Elraglusib and chemotherapy in metastatic pancreatic ductal adenocarcinoma: a randomized controlled phase 2 trial - PubMed
5 hours ago
- #Clinical Trial
- #GSK-3β Inhibitor
- #Pancreatic Cancer
- Elraglusib, a GSK-3β inhibitor, combined with gemcitabine and nab-paclitaxel (GnP), improved median overall survival by 2.9 months compared to GnP alone in previously untreated metastatic pancreatic ductal adenocarcinoma.
- The phase 2 trial showed a 38% reduction in death risk with elraglusib/GnP, with median overall survival of 10.1 months vs 7.2 months and 1-year survival rates of 44.1% vs 22.3%.
- Safety was manageable, with common grade 3 or higher adverse events including neutropenia (52.3% vs 30.8%), anemia (25.2% vs 29.5%), and fatigue (16.8% vs 5.1%).
- Exploratory analyses linked baseline circulating immune factors like CXCL2 and TRAIL ligands to improved survival, along with increased intratumoral cytotoxic immune cells.
- Based on these results, a phase 3 trial is being planned to further evaluate elraglusib/GnP as first-line treatment for metastatic pancreatic ductal adenocarcinoma.